JP2022532557A5 - - Google Patents
Info
- Publication number
- JP2022532557A5 JP2022532557A5 JP2021566150A JP2021566150A JP2022532557A5 JP 2022532557 A5 JP2022532557 A5 JP 2022532557A5 JP 2021566150 A JP2021566150 A JP 2021566150A JP 2021566150 A JP2021566150 A JP 2021566150A JP 2022532557 A5 JP2022532557 A5 JP 2022532557A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- domain
- intracellular signaling
- transmembrane domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025031484A JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845311P | 2019-05-08 | 2019-05-08 | |
| US62/845,311 | 2019-05-08 | ||
| PCT/US2020/031796 WO2020227483A1 (en) | 2019-05-08 | 2020-05-07 | Engineered t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031484A Division JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532557A JP2022532557A (ja) | 2022-07-15 |
| JP2022532557A5 true JP2022532557A5 (https=) | 2023-05-15 |
| JP7723887B2 JP7723887B2 (ja) | 2025-08-15 |
Family
ID=73051184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566150A Active JP7723887B2 (ja) | 2019-05-08 | 2020-05-07 | 操作されたｔ細胞 |
| JP2025031484A Pending JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031484A Pending JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12590136B2 (https=) |
| EP (1) | EP3966235A4 (https=) |
| JP (2) | JP7723887B2 (https=) |
| KR (1) | KR20220030933A (https=) |
| CN (2) | CN120939220A (https=) |
| AU (1) | AU2020267641B2 (https=) |
| BR (1) | BR112021022303A2 (https=) |
| CA (1) | CA3139011A1 (https=) |
| CL (1) | CL2021002935A1 (https=) |
| CO (1) | CO2021016480A2 (https=) |
| EA (1) | EA202193074A1 (https=) |
| IL (1) | IL287777A (https=) |
| MA (1) | MA55911A (https=) |
| MX (1) | MX2021013588A (https=) |
| SG (1) | SG11202111973RA (https=) |
| WO (1) | WO2020227483A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CA3139011A1 (en) | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Engineered t cells |
| CA3177181A1 (en) * | 2020-03-27 | 2021-09-30 | 2Seventy Bio, Inc. | T cell receptors |
| US20240366761A1 (en) * | 2021-04-15 | 2024-11-07 | Legend Biotech Ireland Limited | Fusion proteins and uses thereof |
| TW202317602A (zh) * | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| AU2022371471A1 (en) * | 2021-10-20 | 2024-05-02 | Fate Therapeutics, Inc. | Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| CN118922196A (zh) * | 2022-02-18 | 2024-11-08 | 加利福尼亚大学董事会 | 嵌合细胞因子受体促进原代人nk细胞扩增和功能 |
| USD1083734S1 (en) * | 2022-08-01 | 2025-07-15 | Hyundai Motor Company | Wheel for automobile |
| EP4654981A1 (en) * | 2023-01-27 | 2025-12-03 | Gentibio, Inc. | Engineered repair regulatory t cells |
| WO2025047925A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人三重大学 | ハイブリッドｔ細胞受容体 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| EP1783228A1 (en) | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| WO2011024791A1 (ja) | 2009-08-25 | 2011-03-03 | タカラバイオ株式会社 | レチノイン酸存在下でのｔ細胞集団の製造方法 |
| TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| KR102480188B1 (ko) | 2012-09-14 | 2022-12-21 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체 |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| US10584158B2 (en) | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP2944652A1 (en) | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| MA41920B1 (fr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| US10639538B2 (en) | 2015-08-04 | 2020-05-05 | Fiberbuilt Manufacturing Inc. | Golf practice device |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| SMT202200306T1 (it) | 2016-04-08 | 2022-09-14 | Immunocore Ltd | Recettori di cellule t |
| DK3440106T3 (da) | 2016-04-08 | 2021-10-04 | Adaptimmune Ltd | T-cellereceptorer |
| AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| JP6699423B2 (ja) | 2016-07-21 | 2020-05-27 | コニカミノルタ株式会社 | 定着装置および画像形成装置 |
| MX2019003768A (es) * | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| WO2018225732A1 (ja) | 2017-06-05 | 2018-12-13 | 国立大学法人三重大学 | Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質 |
| US20210147550A1 (en) | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019238023A1 (en) | 2018-06-11 | 2019-12-19 | Chineo Medical Technology Co., Ltd. | Neoantigen vaccines and uses thereof |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CA3139011A1 (en) | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Engineered t cells |
-
2020
- 2020-05-07 CA CA3139011A patent/CA3139011A1/en active Pending
- 2020-05-07 JP JP2021566150A patent/JP7723887B2/ja active Active
- 2020-05-07 SG SG11202111973RA patent/SG11202111973RA/en unknown
- 2020-05-07 BR BR112021022303A patent/BR112021022303A2/pt unknown
- 2020-05-07 MA MA055911A patent/MA55911A/fr unknown
- 2020-05-07 CN CN202510969431.7A patent/CN120939220A/zh active Pending
- 2020-05-07 US US17/608,860 patent/US12590136B2/en active Active
- 2020-05-07 MX MX2021013588A patent/MX2021013588A/es unknown
- 2020-05-07 EA EA202193074A patent/EA202193074A1/ru unknown
- 2020-05-07 CN CN202080044323.4A patent/CN114375301B/zh active Active
- 2020-05-07 AU AU2020267641A patent/AU2020267641B2/en active Active
- 2020-05-07 WO PCT/US2020/031796 patent/WO2020227483A1/en not_active Ceased
- 2020-05-07 EP EP20802730.0A patent/EP3966235A4/en active Pending
- 2020-05-07 KR KR1020217039633A patent/KR20220030933A/ko active Pending
-
2021
- 2021-11-01 IL IL287777A patent/IL287777A/en unknown
- 2021-11-08 CL CL2021002935A patent/CL2021002935A1/es unknown
- 2021-12-02 CO CONC2021/0016480A patent/CO2021016480A2/es unknown
-
2025
- 2025-02-28 JP JP2025031484A patent/JP2025078698A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532557A5 (https=) | ||
| JP2019535275A5 (https=) | ||
| JP7649370B2 (ja) | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 | |
| Medrano et al. | Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy | |
| Sinkovics et al. | New developments in the virus therapy of cancer: a historical review | |
| Tang et al. | T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo | |
| CN111511911B (zh) | 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞 | |
| AU2015230741B9 (en) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof | |
| Siew et al. | Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity | |
| WO2020247392A1 (en) | Combinations of engineered natural killer cells and engineered t cells for immunotherapy | |
| Caron et al. | How to train your dragon: harnessing gamma delta T cells antiviral functions and trained immunity in a pandemic era | |
| KR20250117744A (ko) | Hla-cw8 제한된 돌연변이 kras를 인식하는 t 세포 수용체 | |
| CN115896120A (zh) | 表达免疫功能调控因子的免疫活性细胞及表达载体 | |
| Teigler et al. | Differential inhibitory receptor expression on T cells delineates functional capacities in chronic viral infection | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| JP2022532556A5 (https=) | ||
| JP2019532674A5 (https=) | ||
| JP2025511872A5 (https=) | ||
| US12590139B2 (en) | MHC class II molecules and methods of use thereof | |
| CA3151106A1 (en) | Tcr constructs specific for ebv-derived antigens | |
| Momayyezi et al. | Viral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy? | |
| KR20220148809A (ko) | Hbv 특이적 tcr 라이브러리 및 맞춤형 의약으로서의 이의 용도 | |
| Takahashi et al. | Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| Mingari et al. | Phenotypic and functional analysis of human CD3+ and CD3− clones with “lymphokine‐activated killer”(LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin‐2 |